Enoximone - Docslib

Sign Up
Log In
Upload

Sign Up
Log In
Upload

Home
» Tags
» Enoximone

Enoximone

CASE REPORTS Rhabdomyolysis Following Cardiopulmonary Bypass and Treatment with Enoximone in a Patient Susceptible to Malignant
Drug Therapy of Heart Failure
Phosphodiesterase Inhibitors: Their Role and Implications
Toxic, and Comatose-Fatal Blood-Plasma Concentrations (Mg/L) in Man
(12) Patent Application Publication (10) Pub. No.: US 2007/0208029 A1 Barlow Et Al
Comparison of Enoximone, Amrinone, Or Levosimendan Enriched St
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
Pharmacological Manipulation of Cgmp and NO/Cgmp in CNS Drug Discovery T
(12) Patent Application Publication (10) Pub. No.: US 2004/0077723 A1 Granata Et Al
(12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
A Review of the Herbal Phosphodiesterase Inhibitors; Future Perspective of New Drugs
Celltransmissions Newsletter
(12) Patent Application Publication (10) Pub. No.: US 2009/0005327 A1 GRANATA Et Al
Effects of Low-Dose Oral Enoximone Administration on Mortality
Advances in Targeting Cyclic Nucleotide Phosphodiesterases
Characterization of the First Potent and Selective PDE9 Inhibitor Using A
Decision Trees to Characterise the Roles of Permeability and Solubility on the Prediction of Oral Absorption
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

Top View

Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
FAST TOXICOLOGICAL SCREENING KIT by LC-MS/MS – Code SC9005B
Evidence-Based Patient Safety Advisory: Malignant Hyperthermia
Transdermal Device Containing
Only to Be Used Under the Direction of a Consultant Cardiologist
Inal Articles
Pharmaceutical Appendix to the Tariff Schedule 2
Inotropes Do Not Increase Mortality in Advanced Heart Failure
POTENTIATION, by ENOXIMONE, of SELECTIVE 0-1 and 0-2-ADRENOCEPTOR STIMULATION in HUMAN ATRIAL MYOCARDIUM Welwyn,Herts, AL6 9AR A
Customs Tariff - Schedule Xxi - 1
WO2 Ll/ 32 Al
Classification of Phosphodiesterases and the Therapeutic Effects of Their Inhibitors (Review)
Centre for Reviews and Dissemination
New Positive Inotropic Agents
Therapeutic and Toxic Blood Concentrations of More Than 1100 Drugs and Other Xenobiotics
Mesh Terms for 2002
Pharmaceutical Appendix to the Tariff Schedule 2
Inotropes Are Not Linked to Increased Mortality in Heart Failure

© 2024 Docslib.org Feedback